The gaining effect of ginsenoside Rg3 on EGFR-TKI combination in anti-lung-cancer therapy was fully demonstrated, and a sequential dosing regimen that was more effective than the concurrent dosing regimen was proposed. Here, EGFR is linked to lung carcinoma.